[ad_1] LONDON (Reuters) – Fugitive billionaire jeweller Nirav Modi was denied bail in a London court on Friday, following his arrest last week on charges over his alleged involvement in a $2 billion fraud at
[ad_1] RIYADH (Reuters) – Saudi Basic Industries Corp’s (SABIC) investment plans will not be affected by oil giant Aramco’s purchase of a 70 percent stake in the company, its chief executive said on Friday, adding
[ad_1] (Reuters) – Wall Street’s main indexes rose on Friday, with the S&P 500 set to post its best quarterly performance in nine and a half years, on renewed trade optimism as the latest round
[ad_1] (Reuters) – AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world’s biggest cancer
[ad_1] HONG KONG (Reuters) – China’s Huawei Technologies called on Washington to drop the “loser’s attitude” and once again rubbished U.S. allegations its gear could be used by Beijing for spying, as its network business
[ad_1] (Reuters) – Analysts have turned cautiously optimistic on crude oil prices this year, predicting that production cuts by OPEC and its allies along with U.S. sanctions on Iran and Venezuela will defy headwinds from
[ad_1] NEW DELHI (Reuters) – Jet Airways’ investors are cheering this week’s government-led rescue deal, but the cash-strapped Indian airline’s future looks mired in uncertainty as convincing a new investor to come on board may
[ad_1] LONDON (Reuters) – British house prices picked up only a little bit of speed this month as the approach of Brexit weighed on the housing market, data from mortgage lender Nationwide showed on Friday.
[ad_1] HONG KONG (Reuters) – Electric vehicle start-up Leap Motor, co-founded by surveillance equipment maker Dahua Technology, is seeking to raise 2.5 billion yuan ($372 million) in its latest funding round to finance growth, three
[ad_1] TOKYO (Reuters) – AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi’s cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion
HubTrades is authorized by The Financial Commission, an independent external dispute resolution (EDR) organization, allowing the company and its customers a wide range of services and membership benefits including customer protection in case of disputes, up to €20,000 per case.our customers are insured for the safety of funds.
HubTrades Capital Co., Limited is regulated by the Financial Market Conduct Authority (FSA) of St. Vincent and the Grenadines of the Commonwealth of Nations. The FSA regulatory number is 26737 IBC.
RISK WARNING:
Trading Foreign Exchange and Contracts for Difference (CFDs) is highly speculative and may not be suitable for all investors. HubTrades offers trading on margin. The leverage created by trading on margin can work against you as well as for you. Losses can exceed your entire investment. Only invest with money you can afford to lose and ensure that you fully understand the risks involved. Please ensure you read our Risk Disclosure and Terms and Conditions in full before opening an account with HubTrades.
Restricted Regions: HubTrades does not provide services for residents of certain countries, such as the United States, North Korea, Myanmar, Cuba, Sudan, Syria and some other regions.
Google PlayStore and Apple AppStore are the property of their respective trademark holders.